Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun +11 more·2017·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-16-2554

Cited by (983)

Items 701–800 of 983

SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma
Jusen Nong, Kejian Yang, Tianman Li, Chenlu Lan, Xin Zhou, Junqi Liu, Haixiang Xie, Jianzhu Luo, Xiwen Liao, Guangzhi Zhu et al. · 2023 · Aging
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)
Agathe Dehem, Julien Mazières, Ali Chour, Florian Guisier, Marion Ferreira, Maxime Boussageon, Nicolas Girard, Denis Moro‐Sibilot, Jacques L. Cadranel, Gérard Zalcman et al. · 2023 · Lung Cancer
Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study
Jie Peng, Lushan Xiao, Hongbo Zhu, Lijie Han, Honglian Ma · 2023 · Cancer Cell International
Prediction uncertainty estimates elucidate the limitation of current NSCLC subtype classification in representing mutational heterogeneity
Andrei Puiu, Carlos Gómez-Tapia, Maximilian E. R. Weiss, Vivek Singh, Ali Kamen, Matthias Siebert · 2024 · Scientific Reports
A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma
Xuan Zou, Zhihuang Hu, Changjing Huang, Jianhua Chang · 2020 · Medical Science Monitor
Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma
Naoki Yanagawa, Satoshi Shiono, Makoto Endo, Shinya Ogata, Noriyuki Yamada, Ryo Sugimoto, Mitsumasa Osakabe, Noriyuki Uesugi, Tamotsu Sugai · 2020 · Human Pathology
Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report
Se young Han, Balkrishna Jahagirdar, Arkadiusz Zbigniew Dudek · 2020 · Anticancer Research
Co-mutations in tumor immune microenvironment and immunotherapy
Ling Ma, Lingjun Zhu, Zijie Xu, Yongqian Shu · 2021 · Chinese Medical Journal
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Alfredo Addeo, Giuseppe Luigi Banna · 2018 · Translational Lung Cancer Research
A cellular and spatial atlas of TP53 -associated tissue remodeling in lung adenocarcinoma
William Zhao, Benjamin Kepecs, Navin R. Mahadevan, Åsa Segerstolpe, Jason L. Weirather, Naomi R. Besson, Bruno Giotti, Brian Y. Soong, Chendi Li, Sébastien Vigneau et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Harnessing the gut microbiome to enhance cancer immunotherapy: Current advances and future directions in microbiota‐based therapeutic strategies
Binyan Zhao, Bailing Zhou, Qing Li, Chunyan Su, Jing Ma, Li Yang · 2024 · MedComm – Future Medicine
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency
Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu, Kenichiro Kato, Hiromichi Ito, Arisa Ueki, Takeshi Okamoto, Masato Ozaka, Yu Takahashi, Naoki Sasahira · 2025 · Clinical Journal of Gastroenterology
Curing the Incurable: TP53 Mutated Myeloid Neoplasms
Nathan Punwani, Saurabh Chhabra · 2025 · Clinical Lymphoma Myeloma & Leukemia
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Eman R. Elayeh, Shereen Aleidi, Orwa Aboud, Mohammad Semreen, Yasser Bustanji, Lina Dahabiyeh · 2025 · Lung Cancer Targets and Therapy
The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy
Bin Ye, Chunzhi Wu, Xiaoying Quan, Xiaoli Jia, Lin Yao, Lei Lei, Xiaoyan Chen · 2026 · Discover Oncology
Anti‐PD‐1/PD‐L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges
Md Mohiuddin · 2026 · Health Science Reports
Systematic and precise interventions for KRAS-mutant cancers
JingHui Liang, JunXi Wu, Yuan Zhang, Hongyu Wang, YiYang Zheng, Qing He · 2026 · Experimental Hematology and Oncology
Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets
Peng Cao, Yongxia Qin, Dingtao Hu, Tengfei Ge, Peng Zhang, Chao Cheng, Shun Wang, Shuhui Hu, Zhen Zhang, Ling Xu · 2026 · Journal of Translational Medicine
Integrated bioinformatics analysis reveals correlations of high TRIM59 expression with worse prognosis and immune infiltrates in lung adenocarcinoma
Lingge Yang, Yuan Shan Wu, Liangkun You, Binbin Xie, Jun Qiang Lou, Weidong Han, Kai Wang · 2021 · Journal of Bio-X Research
Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer
Sridha Ganesh, Rui Wang, Honglei Chen · 2021 · ONCOLOGIE
Immunological Role of TP53 Somatic Mutation Classification in Human Cancers
Jianfei Fang, Ying Yang, Lina Xie, Wenjuan Yin · 2023 · Journal of Oncology
Correlation between PD-L1 expression status and efficacy of immunotherapy as second-line or later-line therapy in advanced non-small cell lung cancer patients
Jingya Liu, Yingchun Man, Jianing Gao, Xinxin Wang, Lijie Zhang, Mingheng Li, Jiahan Yu · 2024 · European Journal of Cancer Prevention
A phenocopy signature of TP53 loss predicts response to chemotherapy
Hamza Bakhtiar, Marina Nasrin Sharifi, Kyle T. Helzer, Yue Shi, Matthew L. Bootsma, Tianfu Andy Shang, Matthew R. Chrostek, Tracy J. Berg, S. Carson Callahan, Viridiana Carreno et al. · 2024 · npj Precision Oncology
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun · 2024 · OncoTargets and Therapy
The Association of KRAS and P53 Gene Mutations and MDM2 Expression with the Occurrence of Colorectal Cancer
Hany Akeel Al-Hussaniy, Amjad Ibraim Oraibi, Zahraa Salam Al-Tameemi, Ali Hikmat Alburghaif, Meena Akeel Naji, F. Naji · 2025 · Current Cancer Drug Targets
Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report
Shuai Zhu, Shikang Zhao, Qian Zhang, Shuo Li, Dian Ren, Fan Ren, Lingling Zu, Yanye Wang, Lei Xi, Ning Zhou et al. · 2021 · Translational Lung Cancer Research
Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass
Min Zhang, Meng Zhao, Li-fang Jin, Wei-zhang Shen · 2021 · Medicine
Immunotherapy resistance of lung cancer
Xin Yu, Chaonan Han, Chunxia Su · 2022 · Cancer Drug Resistance
Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer
Jia-Yue Zou, Yujie Huang, Jun He, Zuxiong Tang, Lei Qin · 2022 · World Journal of Clinical Cases
Identification and validation of miR-509-5p as a prognosticator for favorable survival in osteosarcoma
Jiekun Guo, Xiang Fang, Jun Min Zhou, Lingguo Zeng, Bin Yu · 2022 · Medicine
Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without KRAS -Mutation or TTF1 -Expression
Miriam Moeller, Florian Schaedlich, Wolfgang Schuette · 2022 · Cancer Control
Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer
Shuang Li, Dawei Zou, Zhaoqian Liu · 2023 · Frontiers in Pharmacology
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter Q.J. Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross Andrew Soo · 2023 · Expert Review of Anticancer Therapy
CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research
Xian Gong, Jianting Du, Ren‐Wang Peng, Chun Chen, Yang Zhang · 2024 · Cancers
Identification of FLRT2 as a key prognostic gene through a comprehensive analysis of TMB and IRGPs in BLCA patients
Yaling Tao, Xiaoling Yu, Huaiwei Cong, Jinpeng Li, Junqi Zhu, Huaxin Ding, Qian Chen, Ting Cai · 2024 · Frontiers in Oncology
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Anastasia Karachaliou, Elias Alexandros Kotteas, Oraianthi Fiste, Konstantinos Syrigos · 2024 · Cancers
Sustained Response to Anti-PD-1 Therapy in Combination with Nab-Paclitaxel in Metastatic Testicular Germ Cell Tumor Harboring the KRAS-G12V Mutation: A Case Report
Jin-feng Pan, Weiqi Yin, Yingzhi Chen, Hui Wang, Wei Wu, Suying Wang, Da Li, Qi Ma · 2024 · Urologia Internationalis
A panorama of lung cancer biomarkers
Ana Sofia Silva Mesquita, Maire Iumi Maeda, Juliana Cabral Duarte Brandão, Nicolle Cavalcante Gaglionone, Igor Campos da Silva, Milena Perez Mak, Éllen Caroline Toledo do Nascimento · 2025 · Surgical and Experimental Pathology
Are lung adenocarcinoma mutations shaping the immune microenvironment?
Philippe Rochigneux, Edward B. Garon · 2018 · Translational Cancer Research
Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma
Yue Zhao, Han Han, Zhendong Gao, Hong Hu, Jiaqing Xiang, Yihua Sun, Haiquan Chen · 2020 · Seminars in Thoracic and Cardiovascular Surgery
Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
Yunfang Yu, Yongjian Chen, Anlin Li, Qiyun Ou, Qingjian Li, Yang Gu, Dagui Lin, Wenda Zhang, Jingshu Wang, Xudong Tang et al. · 2020 · Clinical and Translational Medicine
A Multi-layer Molecular Fresco of the Immune Diversity across Hematologic Malignancies
Davide Bedognetti · 2020 · Cancer Cell
A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
Jiamao Lin, Xiaohui Wang, Chenyue Zhang, Shuai Bu, Chenglong Zhao, Haiyong Wang · 2021 · Frontiers in Immunology
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei et al. · 2022 · International Journal of Cancer
Identification of an immune subtype predicting survival risk and immune activity in hepatocellular carcinoma
Feng Zhao, Nuo Xu, Jiali Yang, Bo Li, Jianwei Shi, Yuanyuan Zheng, Longjin Xu · 2021 · Aging
Identification of Tumor Microenvironment-Related Prognostic lncRNAs in Lung Adenocarcinoma
Ligong Yuan, Li Feng, Shuaibo Wang, Hang Yi, Fang Li, Yousheng Mao · 2021 · Frontiers in Oncology
New Scope of Targeted Therapies in Lung Carcinoma
Archana Bharti Sonkar, Pranesh Kumar, Anurag Kumar Gautam, Biswanath Maity, Sudipta Saha · 2021 · Mini-Reviews in Medicinal Chemistry
Innate and adaptive immunity in cancer
Aatman S. Doshi, Kirtika H. Asrani · 2021 · Elsevier eBooks
Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
Hong‐Shuai Li, Chengming Liu, Yan Wang · 2022 · Future Oncology
Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab
Zhihui Cai, Yuan Yao · 2020 · Journal of International Medical Research
TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia
Catherine Lai, Jayakumar Narayanan Vadakekolathu, Stephen Reeder, SE Church, Tressa Hood, Ibrahim Taha Aldoss, John E. Godwin, Matthew Joseph Wieduwilt, Martha Lucia Arellano, JOHN B. MUTH et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
Shuo Wang, Xiujuan Qu, Zhi Li, Xiaofang Che, Lili Cao, Xianghong Yang, Xuejun Hu, Ling Xu, Kezuo Hou, Yibo Fan et al. · 2021 · Annals of Translational Medicine
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study
Denys Kozakov, Nazarii M. Kobyliak, Sofiia Livshun, Oleksii Seleznov, Olena Koshyk, Alina Matvieieva, Yaroslav V. Shparyk, Oleksii Kolesnik, Yuliia Moskalenko, О. І. Vynnychenko et al. · 2025 · Frontiers in Medicine
KRAS mutation subtypes in metastatic non-small cell lung cancer
Ali AYTAÇ · 2025 · American Journal of Cancer Research
Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients
Mohammad Al Obeed Allah, Esraa Ali, Ivona Krus, Petr Holý, Vojtěch Haničinec, Filip Ambrozkiewicz, Lukáš Rob, Martin Hruda, Marcela Mrhalová, Kateřina Kopečková et al. · 2025 · Cancer Biology & Therapy
Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning
Yuanyuan Wang, Liuchao Zhang, Hongyu Xie, Liuying Wang, Yaru Wang, Shuang Li, Jia He, Meng Wang, Xuan Zhang, Hesong Wang et al. · 2025 · Briefings in Bioinformatics
An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog–mutant cancer
Seong Jin Park, Young Seok Cho, Jae-Hyeon Lee, Sang Yoon Kim, Youngro Byun, Jooho Park, Ha Rin Kim · 2025 · Journal of Controlled Release
KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer
Fumihiro Terasaki, Shogo Kumagai, Akito Fukuda, Yosuke Tanaka, Takuma Irie, Sachiko Ito, Mihoko Yamada, Shunsuke Onoe, Takashi Mizuno, Toshio Kokuryo et al. · 2025 · International Immunology
Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features
Jinjin Li, Ziyi Yang, Liangzhong Liu, Fei Tang, Taihao Zheng, Chao Zhang, Yuan Peng, Zhenzhou Yang, Zhiming Zhou, Benxu Tan et al. · 2026 · BMC Cancer
Complete response to BRICS in Locally advanced pancreatic cancer (pMMR, CPS 30): a case report
Songlong Yang, Liangxiu Shao, Yating Wu, Yonghai Peng, Weiqiang Fan · 2026 · Frontiers in Immunology
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy
Nikhil P. Mankuzhy, Valentina Santo, Jacob Y. Shin, Tafadzwa Lawrence Chaunzwa, Daphna Y. Gelblum, Abraham Jing-Ching Wu, Matthew T. McMillan, Jennifer Ma, David L. Billing, Puneeth Iyengar et al. · 2026 · Journal of Thoracic Oncology
ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer
Qiang Gao, Ying-nan You, Shuo Lian, Chang Pan, Zong-li Zhang, Kang-shuai Li · 2026 · World Journal of Surgical Oncology
Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer
Jia Chen, Qintao Ge, Jun He, Zichen Bian, Haoming Yu, Chun Li, Jialin Meng, Shuiping Yin, Zongyao Hao, Chaozhao Liang et al. · 2026 · Journal of Experimental & Clinical Cancer Research
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC
Solange Peters, Maximilian Johannes Hochmair, Kathryn Cecilia Arbour, Luis Paz-Ares Rodríguez, Martin Reck, Ticiana A.B. Leal, Colin R. Lindsay, Lu Shun, William Nassib William, Alexander I. Spira et al. · 2026 · Future Oncology
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
Kübra Canaslan, Yasemin Başbınar, İlhan Öztop · 2026 · Critical Reviews in Oncology/Hematology
Aging and cancer: current understandings and future perspectives
Qi Li, Yau-Tuen Chan, Junyu Wu, Zhuofeng Jiang, Pengde Lu, Lin Xu, Zixin Feng, Hongchao Yuan, Yibin Feng, Ning Wang · 2026 · Signal Transduction and Targeted Therapy
[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].
Renfang Deng, Yue Zeng, Yue Pan, Chunhong Hu, Fang Wu · 2022 · PubMed Central
Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
Changshun Wu, Kai Zhou, Yan Zheng, Dongxiao Lv, Miaoqing Zhao, Yue Hu, Fei Qi, Xin Wang, Hong Feng · 2022 · Frontiers in Oncology
Epitope identification for p53R273C mutant
Jian Zhang, Minglu Liu, Yin Chen, Zishan Zhou, Ping Wang, Yang Yu, Shunchang Jiao · 2022 · Immunity Inflammation and Disease
Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland
V. Allmann, Daniela Dyntar, Dirk Lehnick, Marco Dressler, Kristin Zeidler, P. Niederberger, Jeanne Godau, Joachim Diebold, Oliver Pascal Gautschi · 2023 · Swiss Medical Weekly
[Advances of Immunotherapy Resistance and Coping Strategies in Non-small Cell Lung Cancer].
Yawan Jing, Hao Zeng, Ruixin Cheng, Panwen Tian, Yalun Li · 2023 · PubMed Central
Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
Jing Wang, Qin Chen, Xinyue Wang, Dingzhi Huang, Richeng Jiang · 2023 · Journal of Comparative Effectiveness Research
Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
Rui Zhou, Fan Tong, Yongchang Zhang, Rui‐Gang Zhang, Yawen Bin, Sheng Zhang, Nong Yang, Xiaorong Dong · 2023 · Frontiers in Oncology
Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors
Priyanka Sahu, Ankita Mitra, Anirban Ganguly · 2024 · International review of cytology
Response to First-Line Pembrolizumab in Metastatic KRAS -Mutated Non-Small-Cell Lung Cancer
Sabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, Arianna Marinello, Laura Giordano, Emilio Bria, Alessio Stefani, Antonio Vitale, Luca Toschi, Ettore D’Argento et al. · 2024 · Future Oncology
Tislelizumab combined with GT chemotherapy for intimal sarcoma of inferior vena cava: A case report
Haihong Liao, Yong Fang, Da Li, Yuefen Pan, Zhongfeng Niu, Tianhong Fu, Zhuoxuan Wu, Jin Sheng, Yong Dong, Shuwen Han et al. · 2024 · Medicine
The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma
Jing Jing Li, Xiao Juan Wu, Mahtab Farzin, Victoria Bray, Jonathan Williamson, Abhijit Pal, Po Yee Yip, Abeer Hagelamin, Pei Ding, Udit Nindra et al. · 2024 · Pathology
Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A review
Hongyang Liu, Min Qiang, Ying Zhang, Hong Wang, Yang Xing, Rui Guo · 2024 · Medicine
Overexpression of TPD52L2 in HNSCC: prognostic significance and correlation with immune infiltrates
Min Lu, Haoyu Xia, Jing Xu, Zijun Liao, Yuwen Li, Hanwei Peng · 2024 · BMC Oral Health
Prediction of prognosis, efficacy of lung adenocarcinoma by machine learning model based on immune and metabolic related genes
Cong Xue, Yizhi Dai, Gui-Long Li, Yi Zhang · 2024 · Discover Oncology
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer
Vaibhavi Pathak, Koichi Tazaki, Minal Çalışkan · 2025 · Human Genetics and Genomics Advances
Classification of lung adenocarcinoma based on senescence-related genes identifies a cluster with immunotherapy resistance and poor prognosis
Xinrui Gao, Xiang Shen, Shasha Huang, Shangke Huang · 2025 · Discover Oncology
Suppressor protein plasma levels and inflammatory indices in colorectal cancer patients
Nino Chigvinadze, Ia Pantsulaia, Teimuraz Lejava, Archil Aladashvili, Tsitsino Atamashvili, Nino Khvichia, Rekhviashvili Kh · 2025 · BMC Cancer
Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib
Mengli Qiu, Peiwen Guo, Sisi Wang, Yong Zhu, Siqi Wu, Huiting Peng, Zehuai Guo, Yanmeng Guo, Jieheng Lin, Yang Cao · 2025 · Frontiers in Pharmacology
FAT1 mutation-related signature predicts survival risk and tumor immunogenicity in lung adenocarcinoma
Lifeng Gao, Xueying Wang, Yixin Xu, Aimin Wang, Wenjing Zhang, Qinghua Wang, Yanfeng Ren · 2025 · Frontiers in Genetics
p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma
Yaoyao Jing, Ying Yuan, Yong Yu, Haifeng Zhao, Hongliang Yang, Xiaofang Wang · 2025 · Discover Oncology
Predictions of Response in Non-small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Using Clinical Data, Deep Learning, and Radiomics.
Chunxiao Wang, Yu-Xin Li, Yang Ji, Kang Yu, Chunhui Qin, Ling Liu, Yun-Jia Shuai, Jia-Hui Chen, Ao Li, Tong Zhang · 2025 · Academic Radiology
[Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].
Shuang Zhang, Jingjing Liu, Ying Cheng · 2017 · Europe PMC (PubMed Central)
[Advances of the Correlation between Driver Gene Status and Immunotherapy in Non-small Cell Lung Cancer].
Jie Chen, Da Jiang, Fang Huang · 2019 · Europe PMC (PubMed Central)
The Treatment for a Patient with Cancer of Unknown Primary: A Case Report
Qingtao Ni, Kaijin Lu, Chi Pan, Shengbin Dai, Peng Wang · 2021 · Dose-Response
A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy
Kun Jin, Mingjing He, Bo Chen, Xianghong Zhou, Chichen Zhang, Zilong Zhang, Dan Hu, Zhongyuan Jiang, Qiang Wei, Shi Qiu et al. · 2022 · Translational Andrology and Urology
Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
Xian Chen, Rui Zhou, Yong Li, Xin Qu, Yanchun Qu, Wenzhu Li, Yong-song Ye, Lirong Liu, Yan-juan Zhu, Hai-bo Zhang · 2022 · Frontiers in Immunology
Establishment and validation of an immune infiltration predictive model for ovarian cancer
Zhenxia Song, Jingwen Zhang, Yue Sun, Zhongmin Jiang, Xiaoning Liu · 2023 · BMC Medical Genomics
Development and validation of an immune-related gene prognostic index for lung adenocarcinoma
Zitao Liu, Yujie Lei, Junting Shen, Guangqiang Zhao, Xi Wang, Yutian Wang, Yujin Kudo, Jun Liao, Yunchao Huang, Tingdong Yu · 2023 · Journal of Thoracic Disease
Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy
Li Wang, Xiangling Chu, Xin Yu, Chunxia Su · 2024 · Heliyon
Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma
Ali Gökyer, Ahmet Küçükarda, Osman Köstek, İvo Gökmen, Erkan Özcan, Sezin Sayın, Ebru Taştekin, Muhammet Bekir Hacıoğlu, Bülent Erdoğan, Sernaz Uzunoğlu et al. · 2021 · Tumori Journal
Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients
Lin Li, Chuan Chen, Chaojun Liu, Li Na Niu, Chunguo Pan · 2022 · Annals of Translational Medicine
Loss of TP53 mediates suppression of Macrophage Effector Function via Extracellular Vesicles and PDL1 towards Resistance against Chemoimmunotherapy in B-cell malignancies
Elena Izquierdo, Daniela Vorholt, Benedict Sackey, Janica L. Nolte, Stuart James Blakemore, Jan Schmitz, Verena Barbarino, Nadine Nickel, Daniel Bachurski, Ludmila Lobastova et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma
Debao Li, Lei Lei, Jinsong Wang, Bo Tang, Jiuling Wang, Rui Dong, Wenjiong Shi, Guo Liu, Tingting Zhao, Yuzhang Wu et al. · 2023 · Frontiers in Genetics
Targeting KRAS mutation in gastrointestinal cancers
Fuat Bicer, Mehmet Akce, Gary Anthony Piazza, Jeremy B. Foote, Bassel F. El‐Rayes · 2023 · F1000Research